
A consumer advocacy group and more than two dozen academics are demanding regulators investigate Louisiana corrections officials and a small company for testing an implantable version of an addiction treatment on inmates, but without following regulations governing clinical trials.
The pilot program involves sustained-release naltrexone implants, which are surgically inserted under the skin in the stomach. The medication is approved by the Food and Drug Administration as a tablet and injectable to treat alcohol and opioid dependence, but not a surgically implanted form of the drug.
What is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.